METHOD FOR PREDICTION OF PREMATURE ABRUPTION OF NORMALLY LOCATED PLACENTA Russian patent published in 2024 - IPC A61B8/06 G01N33/50 G01N33/76 G01N33/66 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics, and can be used for prediction of premature abruption of normally located placenta (PANLP). Presence or absence of subchorionic haematoma in the first trimester of gestation, threatened premature delivery from 22 to 36.6 weeks of gestation is determined, a pulsation index in the uterine arteries is retrospectively assessed according to Doppler measurements within the framework of prenatal ultrasound screening of the first trimester of pregnancy; blood serum levels of pregnancy-associated protein-A, human chorionic gonadotropin are retrospectively assessed. According to the prenatal biochemical screening of the first trimester of pregnancy, there is a risk of developing preeclampsia, calculated at 8–14 weeks using the ASTRAIA program. Peripheral venous blood is sampled on an empty stomach, the level of D-dimers, cholesterol, leukocytes, glucose and insulin is measured, an average portion of urine is sampled, the protein level is determined, and the HOMA-IR index is calculated. Doppler ultrasound is used to determine pulsation index in umbilical arteries, presence of critical blood flow disorders, as well as indices of peripheral vascular resistance in middle cerebral artery of foetus and in umbilical artery, on the basis of which cerebro-placental ratio is calculated. Presence of Negroid acanthosis is visually assessed. Each indicator is evaluated in diagnostic coefficients (DC). Obtained DC values are summed up. If the total DC value is +9.8 and more, a high risk of PANLP is predicted. If the total DC value is -12.6 and less, a low risk of PANLP is predicted.

EFFECT: method enables higher accuracy of prediction of PANLP, which promotes more rational management of pregnancy and improved outcomes, by assessing the aggregate of the most significant indicators.

1 cl, 1 tbl, 3 ex